SBI Securities’s Pasithea Therapeutics KTTA Stock Holding History

SBI Securities’s Portfolio KTTA Stock Details KTTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$518	Hold	1,051	–	–	﹤0.01%	3103
2026 Q2	$542	Hold	1,051	–	–	﹤0.01%	3011
2026 Q1	$780	Hold	1,051	–	–	﹤0.01%	2746
2025 Q4	$1.36K	Hold	1,051	–	–	﹤0.01%	2529
2025 Q3	$769	Hold	1,051	–	–	﹤0.01%	2799
2025 Q2	$758	Buy	+1,051	New	+$1.15K	﹤0.01%	2795

SBI Securities's KTTA Position: Q3 2026 in Review

SBI Securities held its Pasithea Therapeutics (KTTA) position steady in Q3 2026 at 1,051 shares worth $518. The position accounts for ﹤0.01% of the portfolio, ranked #3103.

SBI Securities first reported a position in KTTA in Q2 2025 and has held it in 6 quarters since. The position peaked at $1.36K in Q4 2025. 1 fund tracked by Wall St. Rank holds KTTA as of Q3 2026.

SBI Securities held 1,051 shares of Pasithea Therapeutics worth $518 as of Q3 2026.
SBI Securities left its Pasithea Therapeutics share count unchanged in Q3 2026.
Pasithea Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3103 holding.
SBI Securities first reported a position in Pasithea Therapeutics in Q2 2025 and has held it in 6 quarters since.
SBI Securities's Pasithea Therapeutics position peaked at $1.36K in Q4 2025.
1 fund tracked by Wall St. Rank held Pasithea Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.